Financial Analysis: Celcuity (NASDAQ:CELC) and GeneLink (OTCMKTS:GNLKQ)

GeneLink (OTCMKTS:GNLKQ) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares GeneLink and Celcuity”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Celcuity	N/A	N/A	-$63.78 million	($2.61)	-4.32

Profitability

This table compares GeneLink and Celcuity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Celcuity	N/A	-62.66%	-39.78%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for GeneLink and Celcuity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
Celcuity	0	0	6	1	3.14

Celcuity has a consensus price target of $29.17, suggesting a potential upside of 158.80%. Given Celcuity’s stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than GeneLink.

Institutional and Insider Ownership

63.3% of Celcuity shares are owned by institutional investors. 14.2% of GeneLink shares are owned by company insiders. Comparatively, 15.8% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Celcuity beats GeneLink on 6 of the 8 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Celcuity

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.